All Stories

  1. Age at First Osteoporosis Screening Among Older Women and Men: Is Bone Mineral Density Measurement Ordered Timely?
  2. Assessment of geriatric predictors of adherence to Zoledronic acid treatment for osteoporosis: a prospective follow-up study
  3. Undetected Peripheral Arterial Disease Among Older Adults With Alzheimer’s Disease and Other Dementias
  4. Computerized Tomography–based Diagnosis of Sarcopenia?
  5. Comment on “Metabolic Syndrome and Elevated C-Reactive Protein Levels in Elderly Patients With Newly Diagnosed Depression”
  6. A New Combination Therapy in Severe Acute Pancreatitis—Hyperbaric Oxygen Plus 3-Aminobenzamide
  7. Insulin vs Sulfonylureas for Second-Line Diabetes Treatment
  8. Comment on “Lower lean mass and higher percent fat mass in patients with Alzheimer's disease”
  9. Nutrition interventions in bed rest trials
  10. Sarcopenia is more than simply documenting low skeletal muscle mass
  11. Bioimpedance analysis—The shortcomings
  12. P2‐391: SLEEP STATUS IN DEMENTIA PATIENTS: A NOVEL TARGET FOR CHOICES OF CHOLINESTERASE INHIBITORS?
  13. Effects of valsartan treatment on serum ghrelin level and left ventricular mass index in patients with untreated primary hypertension
  14. Home-Based Exercise and Hip Fracture Rehabilitation
  15. Comment on “Sarcopenic Obesity and Risk of Cardiovascular Disease and Mortality: A Population‐Based Cohort Study of Older Men”
  16. Increased Calcaneal Spur Frequency in Patients with Obesity and Type-2 Diabetes Mellitus
  17. Re. Pre- and perioperative factors affecting infection after living donor liver transplantation
  18. Influences of Treatment with Amlodipine and Valsartan on Bone Turnover Markers and OPG/RANKL/RANK System in Newly Diagnosed Hypertensive Adults; Which is more Beneficial?
  19. Depression and anxiety disorders among gastroenterologic outpatients
  20. Is segmental bioelectrical impedance analysis a valid tool to assess muscle mass in the elderly?
  21. Cognitive and Functional Influences of Vildagliptin, a DPP-4 Inhibitor, Added to Ongoing Metformin Therapy in Elderly with Type 2 Diabetes
  22. Establishing exercise habit is important when assessing lean body mass in elderly
  23. Accurate diagnosis of sarcopenia in the elderly requires correct measurement of muscle mass
  24. P4–204: The association of hand grip strength, skeletal muscle mass, 5‐meter walking speed and bone mineral densitometry in a small population of Turkish elderly
  25. Comment on “Association of anorexia with sarcopenia in a community-dwelling elderly population: results from the ilSIRENTE study”
  26. Comment to “Age-related changes in body composition in a sample of Czech women aged 18–89 years: a cross-sectional study”
  27. Effects of three different medications on metabolic parameters and testicular volume in patients with hypogonadotropic hypogonadism: 3‐year experience
  28. Görme ve Kas Gücü Kaybı ile Gelen Bir POEMS Sendromu Olgusu
  29. Sarcoidosis and IgA nephropathy: a rare association
  30. Ankle brachial index as a predictor of subclinical atherosclerosis in the elderly
  31. Brain derived neurotrophic factor (BDNF) in cardiometabolic physiology and diseases
  32. Atrial Fibrillation and the Hachinski Ischemic Scale
  33. Cálculo do Índice Tornozelo-Braquial
  34. Increase in subcutaneous adipose tissue and fat free mass in women with polycystic ovary syndrome is related to impaired insulin sensitivity
  35. Letter to the Editor
  36. Ankle-brachial Index, Peripheral Arterial Disease, and Diabetic Retinopathy
  37. Diagnosing PAD by calculating the ankle brachial index: Adherence to the guidelines
  38. High plasma level of long Pentraxin 3 is associated with insulin resistance in women with polycystic ovary syndrome
  39. Ankle–Brachial Index as an Indicator of Arterial Stiffness
  40. Calculation Methods of Ankle Brachial Index and Correct Diagnosis of Peripheral Arterial Disease
  41. Very Low Frequency of PAD in People with CHD in Six Middle Eastern Countries
  42. Soluble CD40 ligand, soluble P-selectin and von Willebrand factor levels in subjects with prediabetes: The impact of metabolic syndrome
  43. The relationship of epicardial adipose tissue thickness to clinical and biochemical features in women with polycystic ovary syndrome
  44. Apelin, Prediabetes and Atherosclerosis
  45. Oxidative stress, obstructive sleep apnea and cardiovascular disease
  46. Do cardiovascular disease risk prediction tools need to be updated in Europe?
  47. Decreased small dense LDL levels in Gilbert's syndrome
  48. Peripheral artery disease assessed by ankle-brachial index in patients with established cardiovascular disease or at least one risk factor for atherothrombosis - CAREFUL Study: A national, multi-center, cross-sectional observational study
  49. Coincidence of Membranous Glomerulonephritis and Autoimmune Thyroiditis: A Case Report
  50. Non-alcoholic fatty liver disease and adipocytokines
  51. Plasma Apelin and ADMA Levels in Patients with Essential Hypertension
  52. Chitotriosidase activity predicts endothelial dysfunction in type-2 diabetes mellitus
  53. Clinical usefulness of AGEs as a biomarker for the attenuation of NASH
  54. The relation of ADMA and apelin to endothelial dysfunction and angiogenesis in patients with type 2 diabetes mellitus
  55. Orlistat for overweight subjects with nonalcoholic steatohepatitis†
  56. Soluble CD40 ligand and soluble P-selectin levels in Gilbert's syndrome: A link to protection against atherosclerosis?
  57. Adipocytokine Levels in Chronic Pancreatitis
  58. P0077 INCIDENTAL DIAGNOSIS OF PEYRONIE DISEASE IN CASE WITH CARSINOID SYNDROME
  59. LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia
  60. NASH and Cardiovascular Biomarkers
  61. Adiponectin levels in patients undergoing coronary stenting
  62. Effect of a hypocaloric diet on serum visfatin in obese non-diabetic patients
  63. Hepatic steatosis, visceral adiposity, insulin resistance, adiponectin, and inflammation
  64. Serum adipokine levels in the obese people
  65. Rosiglitazone for Nonalcoholic Steatohepatitis
  66. Ewing’s sarcoma of the fibula presenting with venous thrombosis
  67. Nonalcoholic steatohepatitis is frequently accompanied by metabolic diseases
  68. Asymmetric dimethylarginine levels decrease because of insulin infusion: is it an unexpected finding?
  69. The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus
  70. Adipokines and cytokines in non‐alcoholic fatty liver disease
  71. Metabolic Syndrome is Related to Nonalcoholic Steatohepatitis in Severely Obese Subjects
  72. Ultrastructural changes in hepatocytes after taurine treatment in CCl4 induced liver injury
  73. Maprotiline induced weight gain in depressive disorder: Changes in circulating ghrelin and adiponectin levels and insulin sensitivity
  74. Allopurinol in Rat Chronic Pancreatitis
  75. Tegaserod-Related Possible Drug Interactions
  76. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance
  77. Platelet Aggregation is not Enhanced in Patients with Prediabetes
  78. Antioxidant Treatment with Taurine Ameliorates Chronic Pancreatitis in an Experimental Rat Model
  79. The effect of fluvastatin on plasma adiponectin levels in dyslipidaemia
  80. Adiponectin and Insulin Resistance in Young and Healthy Smokers
  81. Plasma Adiponectin and Insulin Resistance in New Onset Hypertension
  82. Soluble CD40 Ligand Levels in Otherwise Healthy Subjects With Impaired Fasting Glucose
  83. Hyperbaric oxygen-induced changes in bacterial translocation and acinar ultrastructure in rat acute necrotizing pancreatitis
  84. Panic Attack Precipitated by Tegaserod plus Fluoxetine
  85. The Effect of Combination Therapy of Hyperbaric Oxygen, Meropenem, and Selective Nitric Oxide Synthase Inhibitor in Experimental Acute Pancreatitis
  86. Deferoxamine and Meropenem Combination Therapy in Experimental Acute Pancreatitis